Avastin on par with Lucentis in eye trial Read more: Avastin on par with Lucentis in eye trial – San Francisco Business Times

San Francisco Business Times – by Ron Leuty

Genentech Inc.’s Avastin is as effective as the South San Francisco biotech giant’s Lucentis in treating wet age-related macular degeneration, according to results of a study published in the journal Eye.

The study could help Avastin, the world’s leading cancer fighter that already is used off-label by doctors to treat the eye disease, win formal Food and Drug Administration approval for wet age-related macular degeneration, the Los Angeles Times reported.

That could have implications for Genentech and wet AMD patients. Avastin costs about $50 per injection while Lucentis, which is chemically similar, costs about $2,000.

Genentech, owned by Swiss drug company Roche Group, has tried over the past few years to limit Avastin’s off-label use.

The study included 22 people, and a Genentech spokesman noted that Lucentis has been studied in 10 trials of more than 5,500 people total. What’s more, Genentech said, the results are not statistically significant.

The study led by Boston University School of Medicine’s Dr. Manju Subramanian — the first head-to-head look at Avastin and Lucentis — follows a June report by British researchers that said Avastin is better than the standard treatment for wet AMD in the United Kingdom, the Times reported. That study did not compare Avastin and Lucentis, since Lucentis was not available in the U.K. when the study began.

Lucentis won U.S. approval in June 2006 to treat wet AMD.

A human monoclonal antibody, Avastin is approved in the United States to treat types of colon, lung, breast, kidney and brain cancers. The Food and Drug Administration is considering whether to withdraw conditional approval of the drug for women with previously untreated advanced HER2-negative breast cancer or expand its use with other chemotherapy agents.

Avastin had sales of nearly $6 billion last year.

Courtesy of the Doctors at Shady Grove Eye and Vision Care; Optometrists, Ophthalmologists and Opticians working together to help you see better.  Serving the Rockville, Potomac and Gaithersburg Maryland suburbs of Washington, DC for over 40 years. For more information visit youreyesite.com or call (301) 670-1212

Connect with us on Twitter @EyeInfo and subscribe (free subscription) to this blog

Advertisements

3 Responses

  1. Avastin on par with Lucentis in eye trial Read more: Avastin on ……

    I found your entry interesting do I’ve added a Trackback to it on my weblog :)…

  2. Avastin on par with Lucentis in eye trial Read more: Avastin on par with Lucentis in eye trial ? San Francisco Business Times…

    I found your entry interesting do I’ve added a Trackback to it on my weblog :)…

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: